(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to an oligometastatic renal cell carcinoma (RCC) session. Dr. Raquibul Hannan discussed the role of stereotactic ablative body radiotherapy in this setting.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to an oligometastatic renal cell carcinoma (RCC) session. Dr. Shawn Dason discussed the role of cytoreductive nephrectomy and surgical metastatectomy in this setting.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to an oligometastatic renal cell carcinoma (RCC) session. Dr. Karen Runcie discussed the role of systemic therapy for the treatment of such patients.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a session on prioritizing and sequencing therapy for advanced prostate cancer. Dr. Julie Graff discussed the timing of Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP) inhibitors use for prostate cancer patients with defects in homologous recombination repair (HRR) genes.
(UroToday.com) The 2023 ASCO annual meeting included a session on doublet or triplet therapy for metastatic renal cell carcinoma (RCC), featuring a presentation by Dr. Naomi Haas discussing factors that influence decision-making. Dr. Haas started her presentation by highlighting two case presentations. The first patient was a 61-year-old male who works full time, is a runner, has an ECOG performance score of 0, and has a medical history of hypertension on an ACE inhibitor who presented with anemia (Hgb 10.0 g/dL). He was subsequently diagnosed with a large renal mass (biopsied clear cell RCC) with pulmonary nodules and a solitary liver metastases. The treatment options provided by Dr. Haas are as follows:
(UroToday.com) The 2023 ASCO annual meeting included a session on doublet or triplet therapy for metastatic renal cell carcinoma (RCC), featuring a presentation by Dr. Katy Beckermann discussing the case for triplet therapy. Dr. Beckermann started by highlighting that triplet therapy for testicular cancer, BEP chemotherapy, increases cure rates without increasing toxicity.
(UroToday.com) The 2023 ASCO annual meeting included a session on doublet or triplet therapy for metastatic renal cell carcinoma (RCC), featuring a presentation by Dr. Laurence Albiges discussing the case for doublet therapy. Dr. Albiges started her presentation by highlighting seven reasons (and using these reasons for the format of her talk) for the case for doublet therapy:
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a prostate, testicular, and penile cancers poster session. Dr. Dong-Woo Kang presented the rationale and study framework for a prospective, multicenter cohort natural history study of precision-based genomics in prostate cancer.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a prostate, testicular, and penile cancers poster session. Dr. Dong-Woo Kang presented the rationale and study framework for the POWER trial, which aims to evaluate exercise to enhance cardiovascular health among Black patients with prostate cancer treated with androgen deprivation therapy (ADT).
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a prostate, testicular, and penile cancers poster session. Dr. Veda Giri presented the results of TARGET (Technology-enhanced acceleration of germline evaluation for therapy), a randomized controlled trial (RCT) of a pretest patient-driven webtool versus genetic counseling for prostate cancer germline testing.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a prostate, testicular, and penile cancers poster session. Nonna Shakhnazaryan presented the results of a single institution analysis evaluating sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer patients, detected via PET-based imaging.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a prostate, testicular, and penile cancers poster session. Dr. Ciara McNevin presented the results of an analysis of a large, prospective prostate cancer cohort examining the prevalence of mismatch repair deficiency mutations.
(UroToday.com) The 2023 ASCO annual meeting included a session on the management of prostate cancer in older adults, featuring a presentation by Dr. Ravi Parikh discussing known and novel intervention strategies for helping our elders survive and thrive with prostate cancer. Dr. Parikh started by noting that the “frailty phenotype” in prostate cancer is as follows:
(UroToday.com) The 2023 ASCO annual meeting included a session on the management of prostate cancer in older adults, featuring a presentation by Dr. Alicia Morgans discussing applying risk/benefit considerations for elder patients to current treatment advances in prostate cancer. Dr. Morgans started by emphasizing that when evaluating the patient we need to take a five step approach:
(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a discussant presentation by Dr. David Braun discussing combination therapies coming of age in kidney cancer. Dr. Braun started by highlighting that that there has been an evolving landscape of systemic therapies for RCC over the last 3 decades, highlighted by the cytokine era of the early 1990s, the molecularly targeted therapy era of the early 2000s, the immune checkpoint inhibitor era in the mid 2010s, followed by the combination therapy era starting in the late 2010s:
(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Thomas Hutson discussing the final prespecified overall survival analysis of CLEAR, the 4-year follow-up of lenvatinib + pembrolizumab vs sunitinib in patients with advanced RCC. In the phase 3 CLEAR trial, lenvatinib + pembrolizumab showed clinically meaningful and statistically significant benefits in progression free survival (primary endpoint) and overall survival, and improved objective response rate compared with sunitinib in first line advanced RCC.1 Based on the results from CLEAR, lenvatinib + pembrolizumab was approved by regulatory agencies for the first line treatment of adult patients with advanced RCC. At the 2023 ASCO annual meeting, Dr. Hutson and colleagues reported the final prespecified overall survival analysis of lenvatinib + pembrolizumab versus sunitinib with a median follow-up of 4 years.
(UroToday.com) Dr. Felix Feng presented on the use of digital histopathology-based multimodal artificial intelligence scores to predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a session on prioritizing and sequencing therapy for advanced prostate cancer. Dr. Neeraj Agarwal discussed the current treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC), debating in favor of early treatment intensification for mHSPC patients and arguing that ‘more is more’ in this scenario.
(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2nd and June 6th was host to a session on prioritizing and sequencing therapy for advanced prostate cancer. Dr. Anis Hamid discussed the current treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC), debating against routine, early treatment intensification for mHSPC patients and arguing that ‘less is more’ in this scenario.
(UroToday.com) The 2023 ASCO annual meeting included a session on the management of prostate cancer in older adults, featuring a presentation by Dr. Elizabeth Kessler discussing assessment and decision tools for balancing survival and quality of life. Dr. Kessler started her presentation by posing the question: Do we want to live longer or live better? There are several goals of concordant care:
